[Cytokine-regulating activity of anti-virus preparation CelAgripus in Burkitt's lymphoma stable B-cell lines.].

INTRODUCTION

Cytokines activated in response to immunosuppressive viral infections can directly or indirectly affect the neoplastic transformation of B cells. In this study, we studied a new substance designed to produce the antiviral drug CelAgrip (CA, CelAgripus), which exhibits interferon (IFN) and cytokine-inducing activity and, apparently, can be used as an activator of antiviral immunity. Purpose - is to evaluate the cytokine-regulating effect of CA in Burkitt's lymphoma (LB) cell lines latently infected with the Epstein-Barr virus (EBV).

OBJECTIVES

to study the CA-induced expression of the cytokine genes IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IFN-α, IFN -γ, IFN-β, IFN-λ1, IFN-λ2, IFN-λ3, TNF-α in normal and EBV transformed LB cells.

MATERIAL AND

METHODS

Cell line: the human embryo fibroblasts (HEF), Namalva, Daudi, Raji, P3HR-1. Preparations: CA, gossypol-acetic acid (GAA), sodium carboxymethyl cellulose (Na-CMC).

METHODS

RT-PCR and methods for assessing cytotoxicity (MTT and Scepter 2.0 Merck cell counter).

RESULTS

The effect of the CA preparation on the expression of IFN-λ, IL-1β, IL-6, IL-8 and IL-10 genes was revealed.

DISCUSSION: We observed the activation of gene expression of IFN-λ, IL-1β, IL-6, IL-8 and suppression of IL-10 gene activity when treatment CA of LB cells.

CONCLUSION

The substance CA has new effects on the activation of the expression of a number of key cytokine genes in stable Burkitt lymphoma cell lines.